Precision BioSciences, Inc. (DTIL)

10,36 -0,12 (-1,15%) In data: 11:26AM EDT. Mercato aperto.

Precision BioSciences, Inc.

302 East Pettigrew Street
Suite A-100
Durham, NC 27701
United States
919 314 5512
https://www.precisionbiosciences.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 109

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Michael Amoroso	President, CEO & Director	1,07M	N/D	1978
Mr. John Alexander Kelly R.Ph.	CFO & Principal Accounting Officer	660,91k	N/D	1967
Dr. Alan F. List M.D.	Chief Medical Officer	692,17k	N/D	1955
Dr. Jefferson J. Smith Ph.D.	Co-Founder & Chief Research Officer	N/D	N/D	1973
Mei Burris	Director of Investor Relations & Finance	N/D	N/D	N/D
Mr. Dario Scimeca	General Counsel & Secretary	576,43k	N/D	1975
Mr. Bruce Stevens	Vice President of Quality & Compliance	N/D	N/D	N/D
Maurissa Messier	Senior Director of Corporate Communications	N/D	N/D	N/D
Ms. Juli Blanche	Chief People Officer	N/D	N/D	N/D
Mr. Garrett Gincley	Head of Manufacturing	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Governance aziendale

L'ISS Governance QualityScore di Precision BioSciences, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.